Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Fluralaner
Clinical data | |
---|---|
Pronunciation | /ˌflʊərəˈlænər/ FLOOR-ə-LAN-ər |
Trade names | Bravecto |
Other names |
|
License data |
|
Routes of administration |
By mouth (chewable tablets) |
ATCvet code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 20–27%; reduced in the fasted state |
Elimination half-life | 9.3–16.2 days |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.215.812 |
Chemical and physical data | |
Formula | C22H17Cl2F6N3O3 |
Molar mass | 556.29 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
|
Fluralaner (INN) is a systemic insecticide and acaricide that is administered orally or topically. The U.S. Food and Drug Administration (FDA) approved it under the trade name Bravecto for flea treatment in dogs in May 2014 and Bravecto Plus as a topical treatment for cats in November 2019, with warnings about possible side effects in both species. The EU approved the drug in February 2014. Australia approved it for the treatment and prevention of ticks and fleas on dogs in January 2015.
Mode of action
Fluralaner inhibits γ-aminobutyric acid (GABA)-gated chloride channels (GABAA receptors) and L-glutamate-gated chloride channels (GluCls). Potency of fluralaner is comparable to fipronil (a related GABA-antagonist insecticide and acaricide).
Research
Fluralaner is being investigated to determine its ability to reduce the incidence of mosquito-borne diseases as well as bedbugs.
GABA receptor antagonists |
|
---|---|
GABA synthesis inhibitors | |
Glycine receptor antagonists | |
Glutamate receptor agonists | |
Convulsant barbiturates | |
Other |